Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

• Status: Completed
• Trial end date: 2023-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this prospective interventional study is to compare post-intravitreal injection pain between eyes receiving topical bromfenac versus artificial tears as an analgesic after intravitreal injection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wills Eye
• Treatments: Bromfenac; Lubricant Eye Drops

Criteria

Inclusion criteria are:

• Current patient of the Wills Eye Hospital Retina Service including all Mid Atlantic Retina offices

• Clinical indication of bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injection as determined by the treating retina specialist for diseases such as age-related macular degeneration, choroidal neovascularization, diabetic macular edema, diabetic retinopathy, macular edema. proliferative retinopathy, or macular edema associated with retina vein occlusion.

• Age greater than 18

• Patient's that have had at least three prior injections in each eye

Exclusion criteria are:

• Prior ocular surgery (non-cataract)

• Herpetic eye disease

• Uncontrolled uveitis

• Active conjunctivitis, keratitis or keratopathy

• Current unilateral use of prescription eye drops.

• Allergy to NSAID